To include your compound in the COVID-19 Resource Center, submit it here.

Biogen Idec, Sunesis, Takeda deal

Biogen Idec divested two kinase inhibitor cancer programs to Takeda's Millennium Pharmaceuticals Inc. subsidiary as part of a restructuring announced last year. The programs, which

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE